




Contents lists available at ScienceDirect

# International Journal of Cardiology Cardiovascular Risk and Prevention

journal homepage: [www.journals.elsevier.com/international-journal-of-cardiology-cardiovascular-risk-and-prevention](http://www.journals.elsevier.com/international-journal-of-cardiology-cardiovascular-risk-and-prevention)

## Meta-analysis addressing the impact of sodium-glucose Co-transporter-2 inhibitors on the risk for atrial fibrillation among individuals with heart failure with preserved ejection fraction

### ARTICLE INFO

#### Keywords

SGLT-2 inhibitors

Atrial fibrillation

HFpEF

Cardiovascular disease

The formerly published “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” suggest that sodium-glucose co-transporter-2 (SGLT-2) inhibitors can be beneficial in reducing heart failure (HF) hospitalizations and cardiovascular mortality among subjects with HF with preserved left ventricular ejection fraction (HFpEF) [class of recommendation: 2a] [1]. In a recently published, updated meta-analysis of the dedicated HF trials across the range of left ventricular ejection fraction it was demonstrated that SGLT-2 inhibitors substantially decrease the risk for cardiovascular death and HF hospitalization, a finding that supports their new role as a foundational therapy in HF [2].

It has been demonstrated that SGLT-2 inhibitors produce a significant decrease in the risk for atrial fibrillation (AF), equal to 38% compared to placebo, among subjects with HF with reduced left ventricular ejection fraction (HFrEF) [3]. AF in individuals with HFpEF has been shown to significantly increase the risk for HF hospitalization, compared to their counterparts without AF [4]. In addition, AF is associated with significantly increased risk for progressive HF death in the same population [5]. Therefore, we sought to determine whether SGLT-2 inhibitors affect the risk for incident AF among subjects with HFpEF, exerting an additional cardiovascular benefit.

We searched PubMed database and [clinicaltrials.gov](http://clinicaltrials.gov) from inception to November 1, 2022, for randomized controlled trials (RCTs) enrolling adult subjects with HFpEF, addressing the cardiovascular efficacy and safety of SGLT-2 inhibitors compared to placebo or active control. We applied the following search strategy: ((((((((((SGLT-2 inhibitor) OR (empagliflozin)) OR (dapagliflozin)) OR (canagliflozin)) OR (ertugliflozin)) OR (sotagliflozin)) OR (ipragliflozin)) OR (luseogliflozin)) OR (bexagliflozin)) OR (remogliflozin)) OR (tofogliflozin)) OR (licogliflozin) AND (heart failure with preserved ejection fraction) OR (HFpEF).

We did not impose any filter regarding study setting, sample size, study duration or publication language. We set as primary efficacy outcome the effect of SGLT-2 inhibitors compared to control on the risk for incident AF.

Three independent reviewers (D.P., T.M. and A.D.) extracted the data from the eligible reports, by using a pilot tested, data extraction form. As we assessed only a dichotomous variable, difference was

calculated with the use of risk ratio (RR), with 95% confidence interval (CI), after implementation of the Mantel-Haenszel (M – H) random effects formula. Statistical heterogeneity among studies was assessed by using  $I^2$  statistics. Analyses were performed at the 0.05 significance level, while they were undertaken with RevMan 5.3 software. Publication bias was assessed visually by the inspection of the corresponding funnel plot.

In total, we pooled data from 5 eligible RCTs, 3 of which have already been published [6–10]. SGLT-2 inhibitors, compared to placebo, resulted in a non-significant effect on the risk for incident AF (RR = 1.19, 95% CI; 0.94–1.50,  $I^2$  = 0%,  $p$  = 0.14), as depicted in Fig. 1. Subgroup analysis by the type of utilized SGLT-2 inhibitor revealed that neither dapagliflozin (RR = 1.26, 95% CI; 0.87–1.84,  $I^2$  = 0%,  $p$  = 0.22) nor empagliflozin (RR = 1.14, 95% CI; 0.85–1.53,  $I^2$  = 0%,  $p$  = 0.37) had a significant effect on the risk for AF. Exclusion of the 2 unpublished RCTs did not have a significant impact on the generated effect on the risk for AF (RR = 1.18, 95% CI; 0.94–1.50,  $I^2$  = 0%). Inspection of the corresponding funnel plot did not reveal any asymmetry, indicative of publication bias.

We consider as main limitation of the present analysis the lack of access to individual participants' data, to perform subgroup analyses according to baseline characteristics of interest (medication, medical history, etc.). In addition, 2 out of 5 eligible RCTs are unpublished, and thus may introduce some form of bias. Of course, it has to be admitted that none of the eligible RCTs utilized Holter monitoring for the detection of AF, and thus some cases may have been missed.

In conclusion, the present analysis failed to demonstrate that SGLT-2 inhibitors have a beneficial effect by decreasing the risk for incident AF among individuals with HFpEF, similar to that seen with this drug class in the HFrEF population. Further, dedicated RCTs in the HFpEF population are required to shed further light on this important research question.

#### Funding

None.

<https://doi.org/10.1016/j.ijcrp.2022.200161>

Received 8 November 2022; Accepted 23 November 2022

Available online 26 November 2022

2772-4875/© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. 1. Effect of SGLT-2 inhibitors compared to control on the risk for AF among individuals with HFpEF.

## Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgments

none.

## References

- [1] P.A. Heidenreich, B. Bozkurt, D. Aguilar, L.A. Allen, J.J. Byun, M.M. Colvin, A. Deswal, M.H. Drazner, S.M. Dunlay, L.R. Evers, J.C. Fang, S.E. Fedson, G. C. Fonarow, S.S. Hayek, A.F. Hernandez, P. Khazanie, M.M. Kittleson, C.S. Lee, M. S. Link, C.A. Milano, L.C. Nnacheta, A.T. Sandhu, L.W. Stevenson, O. Vardeny, A. R. Vest, C.W. Yancy, AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines, *J Am Coll Cardiol* 2022 79 (2022) 1757–1780, <https://doi.org/10.1016/j.jacc.2021.12.011>.
- [2] M. Vaduganathan, K.F. Docherty, B.L. Claggett, P.S. Jhund, R.A. de Boer, A. F. Hernandez, S.E. Inzucchi, M.N. Kosiborod, C.S.P. Lam, F. Martinez, S.J. Shah, A. S. Desai, J.J.V. McMurray, S.D. Solomon, SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials, *Lancet* 400 (2022) 757–767, [https://doi.org/10.1016/S0140-6736\(22\)01429-5](https://doi.org/10.1016/S0140-6736(22)01429-5).
- [3] D. Sfairopoulos, T. Liu, N. Zhang, G. Tse, G. Bazoukis, K. Letsas, C. Goudis, H. Milonias, A. Vrettos, P. Korantzopoulos, Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials, *Heart Fail. Rev.* (2022), <https://doi.org/10.1007/s10741-022-10281-3> (Epub ahead of print).
- [4] E. Yang, J. Vaishnav, E. Song, J. Lee, S. Schulman, H. Calkins, R. Berger, S. D. Russell, K. Sharma, Atrial fibrillation is an independent risk factor for heart failure hospitalization in heart failure with preserved ejection fraction, *ESC Heart Fail* (2022), <https://doi.org/10.1002/ehf2.13836> (Epub ahead of print).
- [5] J. Gierula, C.A. Cole, M. Drozd, J.E. Lowry, S. Straw, T.A. Slater, M.F. Paton, R. J. Byrom, E. Garland, G. Halliday, S. Winsor, G.K. Lyall, K. Birch, M. McGinlay, E. Sunley, P.J. Grant, D.H. Wessels, E.M. Ketiar, K.K. Witte, R.M. Cubbon, M. T. Kearney, Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure, *ESC Heart Fail* (2022), <https://doi.org/10.1002/ehf2.14004> (Epub ahead of print).
- [6] S.D. Solomon, J.J.V. McMurray, B. Claggett, R.A. de Boer, D. DeMets, A. F. Hernandez, S.E. Inzucchi, M.N. Kosiborod, C.S.P. Lam, F. Martinez, S.J. Shah, A. S. Desai, P.S. Jhund, J. Belohlavek, C.E. Chiang, C.J.W. Borleffs, J. Comin-Colet, D. Dobreanu, J. Drozd, J.C. Fang, M.A. Alcocer-Gamba, W. Al Habeeb, Y. Han, J. W. Cabrera Honorio, S.P. Janssens, T. Katova, M. Kitakaze, B. Merkely, E. O'Meara, J.F.K. Saraiva, S.N. Tereshchenko, J. Thierer, M. Vaduganathan, O. Vardeny, S. Verma, V.N. Pham, U. Wilderang, N. Zaozerska, E. Bachus, D. Lindholm, M. Petersson, A.M. Langkilde, DELIVER trial committees and investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction, *N. Engl. J. Med.* 387 (2022) 1089–1098, <https://doi.org/10.1056/NEJMoa2206286>.
- [7] S.D. Anker, J. Butler, G. Filippatos, J.P. Ferreira, E. Bocchi, M. Böhm, H.P. Brunner-La Rocca, D.J. Choi, V. Chopra, E. Chuquiuire-Valenzuela, N. Giannetti, J.E. Gomez-Mesa, S. Janssens, J.L. Januzzi, J.R. Gonzalez-Juanatey, B. Merkely, S.J. Nicholls, S.V. Perrone, I.L. Piña, P. Ponikowski, M. Senni, D. Sim, J. Spinar, I. Squire, S. Taddei, H. Tsutsui, S. Verma, D. Vinereanu, J. Zhang, P. Carson, C.S.P. Lam, N. Marx, C. Zeller, N. Sattar, W. Jamal, S. Schnaidt, J.M. Schnee, M. Brueckmann, S.J. Pocock, F. Zannad, M. Packer, EMPEROR-preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction, *N. Engl. J. Med.* 385 (2021) 1451–1461, <https://doi.org/10.1056/NEJMoa2107038>.
- [8] M.E. Nassif, S.L. Windsor, B.A. Borlaug, D.W. Kitzman, S.J. Shah, F. Tang, Y. Khariton, A.O. Malik, T. Khumri, G. Umpierrez, S. Lamba, K. Sharma, S.S. Khan, L. Chandra, R.A. Gordon, J.J. Ryan, S.P. Chaudhry, S.M. Joseph, C.H. Chow, M. K. Kanwar, M. Pursley, E.S. Siraj, G.D. Lewis, B.S. Clemson, M. Fong, M. N. Kosiborod, The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial, *Nat Med* 2022 27 (2021 Oct 28) 1954–1960, <https://doi.org/10.1038/s41591-021-01536-x>.
- [9] DETERMINE-Preserved - dapagliflozin effect on exercise capacity using a 6-minute walk test in patients with heart failure with preserved ejection fraction, *ClinicalTrials.gov Identifier: NCT03877224*. Accessed at: <https://clinicaltrials.gov/ct2/show/NCT03877224>.
- [10] This study tests empagliflozin in patients with chronic heart failure with preserved ejection fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms. *ClinicalTrials.gov Identifier: NCT03448406*. Accessed at: <https://clinicaltrials.gov/ct2/show/NCT03448406>.

Dimitrios Patoulas<sup>a,b,\*</sup>, Theodoros Michailidis<sup>c</sup>, Athina Dimosiari<sup>b</sup>, George Kassimis<sup>a</sup>, Nikolaos Fragakis<sup>a</sup>

<sup>a</sup> Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital “Hippokraton”, Greece

<sup>b</sup> Department of Internal Medicine, European Interbalkan Medical Center, Thessaloniki, Greece

<sup>c</sup> Second Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokraton”, Greece

\* Corresponding author. Second Department of Cardiology, General Hospital “Hippokraton”, Konstantinoupolos 49, 54642, Thessaloniki, Greece.

E-mail address: [dipatoulas@gmail.com](mailto:dipatoulas@gmail.com) (D. Patoulas).